Shah Monarch, Colombo John Paul, Chandna Sanya, Rana Haris
Department of Internal Medicine, Saint Peter's University Hospital, 1050 George Street, Apartment 4i, New Brunswick, NJ 08901, USA.
Department of Pulmonary and Critical Care Medicine, Saint Peter's University Hospital, 1050 George Street, Apartment 4i, New Brunswick, NJ 08901, USA.
Case Rep Hematol. 2021 Nov 5;2021:8774010. doi: 10.1155/2021/8774010. eCollection 2021.
COVID-19 is a respiratory illness that affects the human body in many different ways. The disease carries both thrombotic and hemorrhagic complications, especially in those patients who are anticoagulated to prevent the thromboembolic manifestations. In this report, we discuss a case of retroperitoneal hemorrhage in a patient treated with therapeutic anticoagulation which ultimately led to the patient's death. The literature highlights the importance of anticoagulation because it reduces mortality in patients hospitalized with COVID-19. Although, more recent studies suggest that patients treated with therapeutic anticoagulation are at a higher risk of hemorrhage and increased mortality. Therefore, our case stresses the importance of active monitoring of these patients to detect any suspected case of hemorrhage early to reduce mortality. Overall, more research should be conducted to determine the optimal dosing of anticoagulation that balances safety and efficacy.
新冠病毒病(COVID-19)是一种以多种不同方式影响人体的呼吸道疾病。该疾病会引发血栓形成和出血并发症,尤其是在那些接受抗凝治疗以预防血栓栓塞表现的患者中。在本报告中,我们讨论了一例接受治疗性抗凝治疗的患者发生腹膜后出血的病例,该病例最终导致患者死亡。文献强调了抗凝治疗的重要性,因为它可降低COVID-19住院患者的死亡率。然而,最近的研究表明,接受治疗性抗凝治疗的患者出血风险更高,死亡率也会增加。因此,我们的病例强调了对这些患者进行积极监测的重要性,以便早期发现任何疑似出血病例,从而降低死亡率。总体而言,应开展更多研究以确定平衡安全性和有效性的最佳抗凝剂量。